NanoString Technologies (NASDAQ:NSTG) has collaborated with the MODEL-AD consortium for the development of two nCounter gene expression panels for use in Alzheimer’s disease (AD) research, one for use in mouse studies and another for use in human studies.
These panels measure the expression of 770 genes covering 30 modules discovered in a recent study of human brain tissue.
The collaborators have used the Mouse AD Panel to characterize five IU/JAX MODEL-AD mouse models to date.
Now read: Immunomedics: Contrarian Oncology Pick »
Subscribe for full text news in your inbox